Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China · Delayed Price · Currency is CNY 22.94
+0.82 (3.71%)
Sep 30, 2026, 3:04 PM CST
SHE:300255 Revenue
Hebei Changshan Biochemical Pharmaceutical had revenue of 219.72M CNY in the quarter ending June 30, 2026, a decrease of -5.66%. This brings the company's revenue in the last twelve months to 859.35M, down -9.98% year-over-year. In the year 2025, Hebei Changshan Biochemical Pharmaceutical had annual revenue of 875.13M, down -15.10%.
Revenue (ttm)
859.35M
Revenue Growth
-9.98%
P/S Ratio
24.53
Revenue / Employee
719.72K
Employees
1,194
Market Cap
21.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 875.13M | -155.68M | -15.10% |
| Dec 31, 2024 | 1.03B | -379.63M | -26.92% |
| Dec 31, 2023 | 1.41B | -925.79M | -39.63% |
| Jan 1, 2023 | 2.34B | -631.82M | -21.29% |
| Jan 1, 2022 | 2.97B | 604.26M | 25.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beijing Tiantan Biological Products | 5.65B |
| Yili Chuanning Biotechnology | 4.37B |
| Hualan Biological Engineering | 4.36B |
| Xiamen Amoytop Biotech | 4.02B |
| BrightGene Bio-Medical Technology | 1.36B |
| Sinocelltech Group | 1.25B |
| Evopoint Biosciences | 1.11B |
| Acrobiosystems | 950.35M |